Frank Rimerman Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$557K Buy
6,452
+40
+0.6% +$3.56K 0.03% 386
2026
Q2
$580K Sell
6,412
-107
-2% -$8.96K 0.03% 378
2026
Q1
$522K Buy
6,519
+9
+0.1% +$742 0.03% 368
2025
Q4
$555K Buy
6,510
+414
+7% +$34K 0.04% 355
2025
Q3
$474K Buy
6,096
+102
+2% +$7.97K 0.03% 382
2025
Q2
$469K Sell
5,994
-240
-4% -$17.9K 0.03% 363
2025
Q1
$452K Sell
6,234
-532
-8% -$38.1K 0.04% 333
2024
Q4
$501K Buy
6,766
+1,392
+26% +$97.4K 0.04% 310
2024
Q3
$355K Sell
5,374
-1,421
-21% -$103K 0.03% 389
2024
Q2
$628K Buy
6,795
+6,774
+32,257% +$600K 0.04% 295
2024
Q1
$2.01K Hold
21
– – ﹤0.01% 284
2023
Q4
$1.6K Buy
+21
New +$1.46K ﹤0.01% 279

Other funds holding EW

Frank Rimerman Advisors's EW Position: Q3 2026 in Review

Frank Rimerman Advisors increased its Edwards Lifesciences (EW) stake by 0.62% in Q3 2026, buying an estimated $3.56K and bringing the position to 6,452 shares worth $557K. The position accounts for 0.03% of the portfolio, ranked #386.

Frank Rimerman Advisors first reported a position in EW in Q4 2023 and has held it in 12 quarters since. The position peaked at $628K in Q2 2024. 1,339 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • Frank Rimerman Advisors held 6,452 shares of Edwards Lifesciences worth $557K as of Q3 2026.
  • Frank Rimerman Advisors bought 40 Edwards Lifesciences shares in Q3 2026, an estimated $3.56K.
  • Edwards Lifesciences made up 0.03% of Frank Rimerman Advisors's portfolio in Q3 2026, its #386 holding.
  • Frank Rimerman Advisors first reported a position in Edwards Lifesciences in Q4 2023 and has held it in 12 quarters since.
  • Frank Rimerman Advisors's Edwards Lifesciences position peaked at $628K in Q2 2024.
  • 1,339 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Frank Rimerman Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.